Why Option Care Health Stock Skyrocketed on Tuesday

McKesson and Clayton, Dubilier & Rice agreed to acquire Option Care Health for $32.05 per share, valuing it at about $5.8 billion and representing a roughly 37% premium to Monday's close. Option Care shares rose as much as 33.1% and were up 33% at 1:46 p.m. ET; the stock traded roughly 3% below the offer price. The deal is expected to close in the first half of calendar 2027, subject to shareholder and regulatory approvals, with CD&R holding 51% and McKesson 49% after completion.

Analysis

The key market implication is a long-dated deal spread, not a near-term operating re-rating. At roughly 3% below the stated consideration, OPCH offers limited gross upside against a potentially long wait to the expected first-half 2027 close; that spread can widen sharply on regulatory delay, financing/closing uncertainty, or a deterioration in standalone results. The absence of the usual Q3 call reduces investors’ ability to test the operating trajectory during the wait, making filings and reported metrics more important.

For MCK, the strategic option is more valuable than immediate earnings attribution: it gains a substantial position in alternate-site infusion while CD&R retains majority ownership and Option Care remains separately managed. Do not underwrite near-term integration savings or assume MCK has control. Over 6–18 months, scale could strengthen Option Care’s position with payers and referral channels, while pressuring independent infusion providers and hospital outpatient services; the magnitude depends on payer access, referral retention, and execution, none of which is established by the announcement. Vertical links between a major drug distributor and infusion care may also draw scrutiny, though no specific regulatory obstacle is established.

Contrarian view: the headline premium can obscure the weak standalone setup and the opportunity cost of tying capital up for a modest spread. Conversely, a clean approval path could compress the spread further, leaving little incremental upside for late arb entrants.

Key Decisions for Investors

• Avoid chasing OPCH as an operating-growth story at the deal price. Treat any long position as merger arbitrage: compare the remaining spread with the expected holding period and downside if the transaction breaks; do not annualize the quoted spread without a reliable closing date.
• Watch rather than initiate a directional MCK trade on this announcement alone. Reassess when MCK discloses funding, expected returns, governance rights, and any quantified earnings contribution; the 49% stake and separate management structure limit the case for immediate control synergies.
• Over the next 1–3 months, monitor OPCH’s Q3 results and subsequent operating disclosures for evidence that the standalone business is stabilizing, alongside shareholder and regulatory milestones. The missing items are detailed transaction financing, regulatory review scope, and operating performance under the pending-deal reporting cadence.
• Falsify the merger-arb thesis if approvals are materially delayed or denied, the parties revise or terminate the agreement, or OPCH’s operating deterioration raises deal-completion concerns. A widening spread versus the current level is an early warning; spread compression toward the consideration without improved certainty would reduce prospective reward.